This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Johnson, M. Search for Related Content PubMed PubMed Citation Articles by Johnson, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Thinners Palliative Care Hazardous Substances DB HEPARIN WARFARIN Social Bookmarking                         What's this?

How do palliative physicians manage venous thromboembolism?

Huntershill Marie Curie Centre, Glasgow

This postal survey among 174 UK palliative physicians, aimed to assess current practice and perceived problems within the management of venous thromboembolism (VTE) in patients with advanced cancer. The questionnaire was returned by 131 out of 174 (74%) of the doctors surveyed. The most common estimated incidence of patients with VTE was 1-5%. The diagnosis of VTE is usually confirmed by further investigation and in general, outpatients are more likely to be anticoagulated than inpatients. Problems with anticoagulation include bleeding, international normalized ratio instability, appropriateness of anticoagulation, practical difficulties associated with monitoring, and recurrent VTE. Although probably less effective, 77 out of 128 (60%) of respondents use subtherapeutic regimes in order to minimize the risks. Patients with advanced malignancy and VTE are anticoagulated, if considered appropriate, by the vast majority of palliative physicians in the UK. Warfarin has been abandoned in favour of low-molecular-weight heparin (LMWH) by 26%. LMWH provides anticoagulation with no need for monitoring, has no significant drug interactions and is not affected by liver dysfunction. Theoretically, LMWH is more effective than warfarin in the secondary prevention of VTE with less risk of bleeding.

Key Words: anticoagulants • heparin • low-molecular-weight • neoplasms • questionnaires • thromboembolism

Palliative Medicine, Vol. 11, No. 6, 462-468 (1997)
DOI: 10.1177/026921639701100606


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Soto-Cardenas, G Pelayo-Garcia, A Rodriguez-Camacho, E Segura-Fernandez, A Mogollo-Galvan, and J. Giron-Gonzalez Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice Palliative Medicine, December 1, 2008; 22(8): 965 - 968. [Abstract] [PDF]

				S. Noble, A Nelson, and I. Finlay Factors influencing hospice thromboprophylaxis policy: a qualitative study Palliative Medicine, October 1, 2008; 22(7): 808 - 813. [Abstract] [PDF]

				S Noble The challenges of managing cancer related venous thromboembolism in the palliative care setting Postgrad. Med. J., November 1, 2007; 83(985): 671 - 674. [Abstract] [Full Text] [PDF]

				S. I. Noble and I G Finlay Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study Palliative Medicine, April 1, 2005; 19(3): 197 - 201. [Abstract] [PDF]

				J. Pereira and T. Phan Management of Bleeding in Patients with Advanced Cancer Oncologist, September 1, 2004; 9(5): 561 - 570. [Abstract] [Full Text] [PDF]